Food and Drug Administration approved a generic version of a medication that has proved to be effective—and extraordinarily costly—in the prevention of HIV-1.
FDA approved a generic version of emtricitabine and tenofovir disoproxil fumarate by Teva Pharmacueticals. The medication had been marketed exclusively as Truvada by Gilead Sciences. According to reports, Teva will be able to make the generic version exclusively for some time, although the period wasn’t known.
Emtricitabine and tenofovir disoproxil fumarate has been shown to be effective at preventing the spread of HIV-1 when taken prophylactically and is used to treat HIV-1. It’s approved for adults and children who weigh at least 37.5 pounds.
Truvada, which is taken as a pill once per day, reportedly costs $1,300 per month. It’s unknown what the price will be for the generic version when it becomes available.